A multi-cancer global strategic oncology collaboration between Tokyo, Japan-headquartered Eisai Co. Ltd. and Merck & Co. Inc., the second such deal entered by Merck in the past seven months, was greeted with a near 10% rise in Eisai's share price on the Tokyo Stock Exchange on March 8, as investors digested the announcement, and another from the previous day, when Eisai reported positive top-line Phase III results for its potential sleep disorder therapy, lemborexant (see accompanying article).
Eisai And Merck & Co Supercharge Lenvima's Potential
A global collaboration potentially valued at nearly $6bn will see Eisai's oral tyrosine kinase inhibitor lenvatinib being evaluated in combination with Keytruda in multiple cancer types and indications.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.